BioMedNewsBreaks — Adageis Brings Key Advantages in Pivot to Value-Based Healthcare

Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. “One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards,” reads a recent article. “Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background.”

To view the full article, visit https://ibn.fm/dG4JQ

About Adageis

Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector. For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has re-filed an Abbreviated New Drug Application…

5 hours ago

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL, NXPLW) Issues Q4 Shareholder Update Highlighting Cost Reductions, Healthcare Expansion, and Growth Across Core Channels 

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

6 hours ago

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Need for Advanced 3D Imaging During Breast Cancer Awareness Month

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based technologies for…

9 hours ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia

Oncotelic Therapeutics (OTCQB: OTLC), through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital…

9 hours ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Nutriband (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging…

10 hours ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, announced that its…

1 day ago